Please provide your email address to receive an email when new articles are posted on . This is the first study to investigate treosulfan pharmacogenetics in a large uniform cohort of patients with ...
Credit: Shutterstock. Researchers sought to determine whether luspatercept would improve outcomes in patients with nontransfusion-dependent β-thalassemia. The following article features coverage from ...
Starting iron chelation therapy early may prevent growth problems and organ damage from iron overload in children with TDT. Currently approved medications have limitations for use in very young ...
Sangamo BioSciences ( SGMO) was founded in 1995 ostensibly to commercialize zinc finger nuclease technology. Twenty years have passed since its founding and there hasn't been a single drug approval ...
AAPI Nexus: Asian Americans and Pacific Islanders, Policy, Practice and Community, Vol. 4, No. 2, Youth (Summer/Fall 2006), pp. 111-134 (24 pages) Thalassemia is a potentially life-threatening genetic ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ...
The success of the treosulfan-based conditioning regimen in patients with β-thalassemia undergoing hematopoietic cell transplantation (HCT) is limited due to several complications, such as mixed ...
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EdiGene, Inc., which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug ...
- Data Presented at ASH; Company to Host Investor Call on December 10 - CAMBRIDGE, Mass. – December 8, 2014 – bluebird bio, Inc. (Nasdaq: BLUE) today announced data from eight subjects treated with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback